20 As antimicrobial signalling molecules, type III or lambda interferons (IFNλs) 21 are critical for defence against infection by diverse pathogens. Counter-intuitively, 22 expression of one member of the family, IFNλ4, is associated with decreased 23 clearance of hepatitis C virus (HCV) in the human population; by contrast, a natural 24 in-frame nucleotide insertion that abrogates IFNλ4 production improves viral 25 clearance. To further understand how genetic variation between and within species 26 affects IFNλ4 function, we screened a panel of extant coding variants of human 27 IFNλ4 and identified three variants that substantially affect antiviral activity (P70S, 28 L79F and K154E). The most notable variant was K154E, which enhanced in vitro 29 activity in a range of antiviral and interferon stimulated gene (ISG) assays. This more 30 active E154 variant of IFNλ4 was found only in African Congo rainforest 'Pygmy' 31 hunter-gatherers. Remarkably, E154 was highly conserved as the ancestral residue 32 in mammalian IFNλ4s yet K154 is the dominant variant throughout evolution of the 33 hominid genus Homo. Compared to chimpanzee IFNλ4, the human orthologue had 34 reduced activity due to amino acid substitution of glutamic acid with lysine at position 35 154. Meta-analysis of published gene expression data from humans and 36
expression of one member of the family, IFNλ4, is associated with decreased 23
clearance of hepatitis C virus (HCV) in the human population; by contrast, a natural 24
in-frame nucleotide insertion that abrogates IFNλ4 production improves viral 25 clearance. To further understand how genetic variation between and within species 26
affects IFNλ4 function, we screened a panel of extant coding variants of human 27
IFNλ4 and identified three variants that substantially affect antiviral activity (P70S, 28
L79F and K154E). The most notable variant was K154E, which enhanced in vitro 29 activity in a range of antiviral and interferon stimulated gene (ISG) assays. This more 30 active E154 variant of IFNλ4 was found only in African Congo rainforest 'Pygmy' 31 hunter-gatherers. Remarkably, E154 was highly conserved as the ancestral residue 32 in mammalian IFNλ4s yet K154 is the dominant variant throughout evolution of the 33 hominid genus Homo. Compared to chimpanzee IFNλ4, the human orthologue had 34 reduced activity due to amino acid substitution of glutamic acid with lysine at position 35 154. Meta-analysis of published gene expression data from humans and 36 chimpanzees showed that this difference in activity between K154 and E154 in 37
IFNλ4 is consistent with differences in antiviral gene expression in vivo during HCV 38 infection. Mechanistically, our data suggest that human-specific K154 likely affects 39
IFNλ4 activity by reducing secretion and potency. We postulate that evolution of an 40
IFNλ4 with attenuated activity in humans (K154) likely contributes to distinct host-41 specific responses to and outcomes of infection, such as HCV. 42 43 44
Introduction 45
Vertebrates have evolved the capacity to coordinate their antiviral defences 46 through the action of proteins called interferons (IFNs) (1) , which are small secreted 47 signalling proteins produced by cells after sensing viral infection. IFNs bind to cell Whether other human IFNλ4 variants exist in addition to P70S, which affect 88 antiviral activity, has not been explored fully. In this study, we have examined human 89 genetic data to identify other possible naturally occurring IFNλ4 variants and 90 performed comparative analysis with mammalian orthologues in species closely 91 related to humans. We provide evidence that the antiviral potential for the most 92 common form of IFNλ4 in humans has attenuated activity due to a single amino acid 93
substitution. In addition, we propose that acquisition of the attenuating substitution 94 arose very early during human evolution but that some populations do encode a 95 more active variant. Mechanistically, our data suggest that the reduced antiviral 96 potential of human IFNλ4 results from a likely defect in secretion and potency. 97 98
Results 99
Functional consequences of human IFNλ4 non-synonymous variation 100
Firstly, we undertook genetic and functional comparisons of natural human 101
IFNλ4 coding variants present in the human population. We identified 15 non-102 synonymous HsIFNλ4 variants in the 1000 Genomes Project database (23) (Fig 1A  103 and Supplementary Data File 1), including three previously described variants 104
(C17Y, P60R and P70S; >1% global frequency, classified as 'common') (18). The 105
remaining 12 variants were classified as rare (<1% global frequency). The African 106 population harboured the largest number of, as well as the most unique, variants. 107
Interestingly, three rare variants (A8S, S56R and L79F) were shared exclusively 108
between African and American populations, which may have arisen due to relatively 109 recent movements of people perhaps through the transatlantic slave trade. 110
Variants were located in regions of functional significance in the HsIFNλ4 111 protein (Fig 1B and S1 Fig A-C) , such as the predicted signal peptide (amino acids 112 1-24), surrounding the single glycosylation site (N61) [both of which are required for 113 secretion of active protein], and helix F that is predicted to interact with the IFNλR1 114 receptor (variants 151-158) (24). Interestingly, the variants in helix F were clustered 115 in the N-terminal portion of the predicted helix. Based on the above predictions, we 116
hypothesised that some of these variants may have phenotypic effects on HsIFNλ4 117
function. Of note, no variants were found in helix D, which is predicted to contribute 118
to interaction with the IL-10R2 receptor, nor on the IL-10R2-interacting face of the 119 protein.
120
The functional impact of variation on HsIFNλ4 has only been assessed for the 121 common P70S variant and so we sought to screen all other variants in activity 122 assays. To determine whether variants affected HsIFNλ4 antiviral activity, they were 123
introduced independently into an expression plasmid that produced HsIFNλ4 with a 124 C-terminal 'FLAG' tag. Transient transfection of the expression plasmids into human 125 'producer' cells (HEK-293T cells) allowed harvesting of active HsIFNλ4 in the cell 126
supernatant (referred to herein as conditioned media [CM]) thereby enabling analysis 127
of the effects of variants on HsIFNλ4 production, glycosylation, secretion and 128 potency; a similar approach has been successfully adopted previously to determine 129
the relative activities of secreted HsIFNλ3 and HsIFNλ4 as well as a HsIFNλ4 variant 130 that is not glycosylated (24) . We chose to screen the function of the panel of 131
HsIFNλ4 variants on the interferon-competent hepatocyte cell line HepaRG cells 132
(25). 133
Firstly, we investigated the antiviral activity of variants by titrating them 134 against encephalomyocarditis virus (EMCV), a highly IFN-sensitive and cytopathic 135 virus used to measure IFN-mediated protection (26) (Fig 1C and S2 Fig A) . We also 136 measured their capacity to induce two major ISGs, MX1 and ISG15, by RT-qPCR 137 (Fig 1D and E, and S2 Fig B and C) and validated the ISG15 mRNA data by 138 Fig 1. Rare non-synonymous variants of HsIFNλ4 affect antiviral activity (A) Ancestry-based localization and frequency of human non-synonymous variants of HsIFNλ4 in African (AFR), South Asian (SAS), East Asian (EAS), European (EUR) and American (AMR) populations within the 1000 Genomes dataset. 'n' represents the number of alleles tested in each population. Common and rare variants are those which have frequencies of >1% and <1% respectively in the 1000 Genome data. Common variants include: wt (orange), C17Y (light green), R60P (dark blue) and P70S (cyan). Rare variants (purple) include: A8S, C17R, R25Q, S56R, P73S, L79F, K133M, V134A, R151P, K154E, S156N, and V158I. Variants K133M and S156N (black) did not have an associated ethnicity but were found in the dataset from the Netherlands (Genome of the Netherlands cohort) (69). (B) Location of non-synonymous variants in the HsIFNλ4 polypeptide (underlined pink). Regions of predicted structural significance are boxed (green), including the signal peptide (SP) and helices (A to F) (24). There is a single N-linked glycosylation site at position 61 (N61). Note that there are 2 non-synonymous changes at C17 (C17R and C17Y). Cysteine residues involved in disulphide bridge formation are italicised. See Supplementary Data File 1 for genetic identifiers for the variants described here. (C) Antiviral activity of all HsIFNλ4 natural variants in an anti-EMCV CPE assay relative to wt protein in HepaRG cells. Cells were stimulated with serial dilutions of HsIFNλ4-containing CM for 24 hrs and then infected with EMCV (MOI = 0.3 PFU/cell) for 24 hrs at which point CPE was assessed by crystal violet staining. After staining, the dilution providing ~50% protection was determined. Mean of combined data from three independent experiments (n=3) are shown. Error bars represent mean and SEM for all variants combined. Data are shown in S2 Fig A. **** = <0.0001; *** = <0.001; ** = <0.01 by one-way ANOVA compared to wt with a Dunnett's test to correct for multiple comparisons. Controls (HsIFNλ4-TT and EGFP) are not shown but gave no protection against EMCV in the assay. Those variants with >2-fold change are highlighted with colours: purple (K154E,), cyan (P70S) and yellow (L79F). (D and E) ISG gene expression determined by RT-qPCR following stimulation of cells with HsIFNλ4 variants. Relative fold change of ISG15 (D) and Mx1 mRNAs (E) in HepaRG cells stimulated with CM (1:4 dilution) from plasmid-transfected cells compared to wt HsIFNλ4. Cells were stimulated for 24 hrs. Data points show mean of biological replicates (n=3) and the error bar represents mean and SEM for all variants combined. Expanded data are shown in S2 Fig determining production of unconjugated 'mono' ISG15 and high-molecular weight 139 ISG15-conjugates ('ISGylation'; S2 Fig D) . We also constructed a series of negative 140 controls (plasmids expressing EGFP and the frameshift TT variant of HsIFNλ4), a 141 positive control (HsIFNλ3op) for comparative analysis to examine HsIFNλ4 activity,  142 and three HsIFNλ4 variants, which do not occur naturally but were included as they 143
could alter post-translational modification (N61A which ablates glycosylation) or 144 potential receptor interactions (F159A and L162A located in helix F), respectively 145 (27). Negative controls (EGFP or the frameshift TT variant) gave very low induction 146 of ISG15 and MX1 and no detectable antiviral activity in the EMCV assay whereas 147 the positive control (HsIFNλ3op) was highly active in both assays (S2 Fig A-C) . The 148
non-natural variants N61A and F159A almost abolished activity compared to wt 149
HsIFNλ4 and HsIFNλ3op while L162A gave slightly less activity in the ISG induction 150 assay but activity was reduced to a greater extent in the EMCV assay. In a previous 151 report, ablating glycosylation at N61 substantially reduced activity of secreted 152
HsIFNλ4 in an ISG induction assay (24). Thus, our assay systems recapitulated 153 findings from previous studies with similar assays and provided a range of activities 154
to assess the impact of the natural HsIFNλ4 variants.
155
Our analyses on the natural HsIFNλ4 variants revealed that only three 156 variants (P70S, L79F and K154E) consistently and substantially modulated antiviral 157 activity and signalling compared to wt HsIFNλ4 (Fig 1C-E) . The impact of these 158
variants was particularly pronounced in the EMCV assay that measures the dilution 159
giving 50% activity over a large range of dilutions (Fig 1C) . Our results confirmed 160 previous observations on the lower activity of the P70S variant (22) and 161 demonstrated that the rare L79F variant had a similar phenotype. By contrast, the 162 K154E variant substantially enhanced antiviral activity and ISG induction.
163
These effects on activity for P70S, L79F and K154E did not arise from 164
differences in the levels of HsIFNλ4 intracellular production or changes to 165 glycosylation (S3 Fig A and B) . However, variants S56R and R60P (R60P is a 166 common variant in Africa) did lead to marked reductions in the glycosylated form of findings with the N61A non-natural variant, which abolished both glycosylation and 170 antiviral activity of conditioned media (S2 Fig A-C and S3 Fig A and B) . From this 171 screen, we concluded that three non-synonymous variants in HsIFNλ4 (P70S, L79F 172
and K154E), identified as either common or rare alleles in the human population, 173 affect activity of the protein.
174
Examining the global distribution of genetic variation can help understand its 175 origins, evolution and functional consequences. P70S is a common variant that is 176 found worldwide (in every population in the 1000 Genomes Database). By contrast, 177
L79F and K154E are rare and geographically restricted to West Africa/Americas, and 178
central Africa, respectively (Fig 1A) . From further interrogation of human genome 179 datasets (28), the HsIFNλ4 K154E variant was present in two individuals from 180 different African rainforest 'Pygmy' hunter-gatherer populations (Baka and Bakola) in 181
Cameroon (S4 Fig A) . The Bakola individual was homozygous for the G allele, 182 indicating that the K154E variant would be encoded on one of the functional G 183 s. The Baka subject was heterozygous at rs368234815 (G/TT) and 184 thus could produce either wt or the more active K154E form of HsIFNλ4. Each of 185 these individuals also had additional non-synonymous HsIFNλ4 variants (V158I and  186 R151P, Baka and Bakola individuals respectively); these variants were included in 187 our functional screen of HsIFNλ4 variants but did not significantly alter activity (Fig  188  1C-E and S2 Fig A-C) . K154E was not found in other East or Southern African 189
hunter-gatherer populations (such as Hadza and Sandawe) nor in the African San, 190
who have the oldest genetic lineages among humans (29) (S4 Fig B) ; it was also not 191 identified in Neanderthal and Denisovan lineages (denoted as 'archaic' in S4 Fig B) . Since a lysine residue encoded at positon 154 is unique to humans compared 202 to other mammalian species (Fig 2A) range of dilutions of secreted IFNλs (S5 Fig B) . 210
Although intracellular expression levels of each IFNλ4 variant were similar, 211 (Fig 2B) , wt PtIFNλ4 was significantly more active than HsIFNλ4 in each assay and 212 had approximately equivalent activity to the HsIFNλ4 K154E variant in signalling as 213 well as antiviral assays (Fig 2C-E) . Converting PtIFNλ4 to encode the E154K variant 214 significantly decreased activity to levels that were similar to those for wt HsIFNλ4 215
(encoding lysine at position 154). Extending the analysis to include rhesus macaque 216
IFNλ4 (Macaca mulatta, MmIFNλ4) gave the same pattern whereby wt MmIFNλ4 217 with E154 had greater activity than its K154 variant. However, wt MmIFNλ4 was less 218 active than either the human or chimpanzee IFNλ4 with E154 indicating that other 219 genetic differences likely modified MmIFNλ4 activity in our assays. Introducing a 220 lysine into HsIFNλ3 had a minimal effect on its activity (Fig 2C-E To broaden analysis of the impact of a lysine residue compared to a glutamic 228 acid at position 154 in HsIFNλ4, antiviral assays were conducted with other human 229
viruses that are less sensitive to exogenous IFN compared to EMCV, and on 230 different cell lines. Specifically, we used HCV infection in Huh7 cells as well as 231 infectious assays with influenza A virus (IAV) and Zika virus (ZIKV) in A549 cells 232 against single high dilutions of each IFN. As controls, we also included the less 233 active P70S and L79F HsIFNλ4 variants alongside HsIFNλ3op in these assays. 234
Using the HCVcc infectious system in Huh7 cells, HsIFNλ4 K154E significantly 235
decreased both viral RNA abundance compared to wt protein and exhibited a trend 236 towards a lower number of infected viral antigen (NS5A)-positive cells (Fig 3A, upper  237 and lower panels respectively). Furthermore, we performed assays examining HCV 238 entry (HCV pseudoparticle system [HCVpp]), viral RNA translation and RNA 239
replication (both assessed with the HCV sub-genomic replicon system). There was 240 no significant difference in the efficiency of HCVpp infection between wt HsIFNλ4 241 and any of the three variants tested in the MLV-based pseudoparticle assay (Fig 3B,  242 upper panel). However, we did observe a greater inhibition when the non-HCV 243 E1E2-containing PPs were used, potentially reflecting the higher efficiency of HCVpp 244 entry compared to non-glycoprotein-containing retroviral PPs that could saturate an 245 inhibitory response (Fig 3B, lower panel) . wt HsIFNλ4 reduced HCV RNA replication 246 compared to EGFP and introducing the K154E mutation into wt HsIFNλ4 gave a 247 further significant reduction in replication. (Fig 3C, upper panel) . However, primary 248 translation of input viral RNA was not affected by HsIFNλ addition (Fig 3C, reduced titers of IAV and ZIKV to a greater extent than wt protein in A549 cells (~10-252 fold; Fig 3D and E) . Although this was only statistically significant in the context of 253 IAV, a similar trend was evident with ZIKV for the K154E variant compared to wt 254
HsIFNλ4. We found that the P70S and L79F variants consistently reduced the ability 255 of wt HsIFNλ4 to protect against infection in most assays. Taken together, our data 256 further confirmed the greater antiviral activity associated with converting a lysine 257 residue at position 154 in HsIFNλ4 to a glutamic acid residue. 
Transcriptomic analysis of cells stimulated with HsIFNλ4 variants 260
The enhanced antiviral activity of HsIFNλ4 E154 against multiple viruses in 261 different cell lines suggested that this variant may differentially affect global 262 transcription of antiviral ISGs. To test this hypothesis and examine the impact of 263
HsIFNλ4 on global transcription, A549 cells were treated with wt and variant forms of 264
HsIFNλ4 that had different antiviral activities and transcriptional changes were 265
analysed by RNA-Seq at 24 hrs post stimulation (Fig 4) . A549 cells were used 266 because they recapitulate the functional differences in HsIFNλs as observed in other 267 cell types and are widely used as a cell line model for epithelial antiviral immunity. 268
The data revealed that K154E induced the broadest profile of significantly 269
differentially-regulated genes (n=273) compared with either the wt protein (n=178) or transcriptional programmes with differences in the overall significance of these 274 pathways, most notably enhancement of the antigen presentation and protein 275 ubiquitination pathways with the K154E variant ( Fig 4D) . Many of the differentially-276 expressed genes shared by HsIFNλ4 wt, K154E and P70S included known 277 restriction factors with antiviral activity (e.g. IFI27, MX1, ISG15; Fig 4E) although the 278 magnitude of induction was consistently greatest for HsIFNλ4 K154E (Fig 4F) . There 279
were also several ISGs that only achieved significant induction by K154E and 280
HsIFNλ3op (e.g. IDO1, IRF1 and ISG20; Fig 4E and F) . We predict that the 281 apparent selectivity by IFNλ4 K154E results from the greater potency of this variant 282 compared to wt HsIFNλ4 and the P70S variant allowing genes to reach the 283 significance threshold (Fig 4F) . Enhanced production of antiviral genes in cells 284 treated with HsIFNλ4 E154 would explain differences in antiviral activity against 285 EMCV, HCV, IAV and ZIKV. 286 287
Comparison of human and chimpanzee intrahepatic gene expression during HCV 288
infection 289
Direct in vivo validation of our transcriptomic findings alone on the enhanced 290 activity of the K154E variant would require liver biopsy samples from either HCV-291 data was collated and we focused our comparisons on periods when human and 302 chimpanzee biopsies were taken across the same time period after initial HCV 303
infection (between 8 and 20 weeks post infection). 304
305
Comparative gene expression analysis revealed distinct host responses in 306
humans and chimpanzees as well as overlapping differentially-regulated genes ( Fig  307  5A and Supplementary Data File 3) . In chimpanzees, the transcriptional profile 308
contained significantly expressed genes that were type I/III IFN-regulated ISGs 309 known to restrict HCV infection (RSAD2, IFI27 and IFIT1) (2), as well as genes 310
involved in antigen presentation and adaptive immunity (HLA-DMA and PSMA6). 311
These genes were not significantly differentially expressed in humans, whose 312
response was mainly directed towards up-regulation of pro-inflammatory genes (for 313 example, CXCL10, CCL18 and CCL5) and metabolism genes (AKR1B10 and 314 HKDC1) (Fig 5A and Supplementary Data File 3) . This was consistent with 315 previous characterisation of the human acute response to HCV infection that failed to 316 detect a major type I/III IFN signature but predominantly found a type II or IFN-317 gamma-mediated response (31). From the available longitudinal data, the 318 'chimpanzee-biased' differentially-expressed genes were induced early in infection 319
and remained significantly up-regulated during the acute phase following an early 320 peak after infection (S6 Fig A and B) . Differences were also reflected in pathway 321 analysis in terms of the most significant pathways and their overall levels of 322 significance (Supplementary Data File 3) . For example, the 'chemokine-mediated 323 signalling pathway' was upregulated in humans but not chimpanzees whereas the T 324 cell receptor signalling pathway which was modulated in chimpanzees was not 325 significantly altered in humans. Inspection of the raw data from humans indicated 326 that many apparently 'chimp-biased genes' were expressed but did not reach 327 significance in the original study. These genes were typically induced at a lower level 328
in the human group when compared to averaged values for chimp studies across the 329 similar time period (Fig 5B) . Furthermore, there was a greater induction of antiviral 330
ISGs in chimpanzees during chronic infection in comparison to humans although to a 331 less pronounced effect (S6 Fig C) . 332
From examining the in vivo biopsy data, we identified a group of 29 333 chimpanzee-biased genes in liver biopsies that were up-regulated during acute 334
infection to a greater extent compared to humans. Comparing this set of genes to 335 those from the RNA-Seq transcriptomic data obtained in vitro (Fig 4) showed that the 336 majority (17/29 genes) of the chimpanzee-biased genes were induced by HsIFNλ4 337 stimulation, with approximately half (8 genes) of those being significantly up-338 regulated to a great extent with K154E compared to wt, including MX1, IFITM1, 339 IFIT1, IFIT3, TRIM22 and IFI44L (Fig 5C) . Thus, there are similarities between our in 340 vitro analysis and published in vivo studies that would correlate with differences in 341
IFNλ4 activity between humans and chimpanzees. 342 343
Mechanism of action for the enhanced activity of the HsIFNλ4 E154 variant 344 345
Having established the greater antiviral potential for the E154 IFNλ4 variant and its 346 apparent evolutionary relevance, we set out to determine the possible basis for its 347 enhanced activity. No crystal structure for HsIFNλ4 is available but a homology 348 model based on comparison with the IFNλ3 structure has been reported (24). We 349 expanded this predicted model based on both of the IFNλ1 and IFNλ3 crystal 350 structures to explore the possible impact of K154E, P70S and L79F on IFNλ4 351 function (Fig 6A and S8 Fig; (36,37) ). As has been previously described, the 352 sequences in helix F, which binds to IFNλR1, are relatively well conserved (18,24) 353
The position equivalent to amino acid 154 in IFNλ4 is a glutamic acid in both IFNλ1 354
and IFNλ3 (amino acid position 176 in IFNλ1 and 171 in IFNλ3) and its side chain 355 faces inward towards the opposing IL10R2-binding helices C and D (Fig 6A) . The 356 free carboxyl group of glutamic acid forms non-covalent intramolecular interactions 357
with two non-linear segments on IFNλ1 and 3 (IFNλ1 residue K64, and in IFNλ3 K67 358 and T108). In IFNλ4, these E154-interacting positions are not conserved compared 359
to IFNλ1/3 although homologous positions do exist with biochemically similar 360 residues (IFNλ4 R60, and R98 that lies just upstream of the residue homologous to 361
IFNλ3 T108). 362
To test whether the biochemical properties of glutamic acid at position 154 363 contribute to IFNλ4 activity, a panel of variants was constructed with biochemically 364 distinct amino acids (R154, L154, A154, D154 and Q154). Firstly, intracellular 365 expression of each variant at position 154 was approximately equivalent (Fig 6B) . In 366 signalling assays, the order of activity was E>Q/D>A>L>K>R (S7 Fig A) . We found a 367 similar pattern in the EMCV antiviral assays except that L154 had the least activity 368 (Fig 6C) . We interpret these findings to conclude that E154 is biochemically the most 369 favoured residue at this position with regards to antiviral potential, and that 370 substitution of E154 to lysine results in the lowest potency for IFNλ4 activity. 371
Interestingly, both Q154 and D154 had 'intermediate' activity compared to E154 and 372
K154, suggesting that side chain length and negative charge are important to 373 maximise the activity of IFNλ4. 374
In a final series of experiments aimed at giving further insight into the 375 mechanism of action of IFNλ4 K154E, we compared the relative activities and 376
abundance of different IFNλ4 variants in cell lysates (i.e. intracellular protein) and 377 supernatants (i.e. extracellular protein). As wt HsIFNλ4 is poorly secreted into the 378 supernatant from transfected cells in the absence of enrichment (24,38) IFNλ4 in CM 379
was immunoprecipitated using an anti-FLAG antibody. In antiviral assays, the activity 380 of human, chimpanzee and macaque E154 variants from cell supernatants, IP 381 fractions and lysates was greater than the corresponding K154 variants in 382 agreement with our earlier results (Fig 6D and Fig 2C-E) 386  B) . Thus, each variant displayed a similar pattern of activity irrespective of the 387 source of IFNλ4. From Western blot analysis, the E154 and K154 variants for each 388 individual species were detected at similar levels in cell lysates (S6 Fig E) . The 389
HsIFNλ4 D154 and R154 variants were expressed to slightly higher and lower levels 390 respectively compared to E154 and K154 from humans. Paradoxically, we did not 391
find the same pattern in IFNλ4 abundance for immunoprecipitated protein. Thus, we 392
were able to detect greater amounts of the E154 variants for human, chimpanzee 393 and macaque IFNλ4 compared to their K154 variants (Fig 6E) . It greater and on average 16-fold. For the secreted IFNλ4 variants, we found that not 399
only was there a higher abundance of E154 to K154 protein (9-fold), but activity was 400 41-fold higher for E154 than K154 variants, which results in a significant 3 to 4-fold 401 rise in antiviral activity not explained by protein abundance. With the exception of 402 macaque K154, the FLAG antibody detected a putative breakdown product of about 403 11kDa in each of the samples, which we presume arose from cleavage by an 404
unknown intracellular protease as it was also detected in cell lysates. The amount of 405 this lower molecular weight product follows the same pattern as the full-length 406 protein in that there is more with E154 than K154 thus cleavage does not explain 407 differences in antiviral activity. Therefore, we conclude that glutamic acid at position 408 154 promotes greater antiviral potential by enhancing both IFNλ4 secretion from the 409 cell andto a lesser extent -its intrinsic potency. 410 411
Discussion 412
In this study we have identified further functional variants of human and non-413
human IFNλ4 that expand the spectrum of its activity. By comparing IFNλ4 from 414 different species we demonstrate that the genus Homo evolved an IFNλ4 gene with 415 attenuated activity (prior to the TT allele), and that the vast majority of extant humans 416 carry an IFNλ4 variant with lower antiviral potential due to a mutation of a single 417
highly-conserved amino acid residue (E154K). Human African hunter-gatherer 418
Pygmies and chimpanzees encode a more active IFNλ4 (E154). We speculate that 419 position 154 in IFNλ4 plays a key role in intramolecular interactions that may 420 facilitate stabilisation of the protein thereby influencing its signalling potential and 421 antiviral activity (S9 Fig) In our study of three primate orthologues, glutamic acid at position 154 in 494
IFNλ4 provided greater antiviral activity and enhanced its ability to induce antiviral 495 gene expression. 496 orthologues has been explored previously but no significant differences in signalling 497 activity were observed (30). There are substantial differences in the methodologies 498 used in our study and that of Paquin et al., which could explain our ability to detect 499 divergent activity, for example size of tag attached to IFNλ4 and dose of protein used 500 in assays.
501
Our observed functional differences between E154 and K154 did not correlate 502
with levels of intracellular accumulation or glycosylation. However, we did find that 503 the more active E154 variants for human, chimpanzee and macaque IFNλ4 were 504 detected at higher levels in the immunoprecipitated fractions from cell supernatant 505 (CM) compared to the K154 variants; the D154 and R154 variants also were 506 detected at a lower level than E154. Interestingly, wt HsIFNλ4 with K154 is not 507
secreted efficiently compared to wt HsIFNλ3 (24,38). This was not due to differences 508
in the signal peptide of HsIFNλ4 or HsIFNλ3 but HsIFNλ4 secretion could be ablated 509
if the single N-linked glycosylation site was mutated (24). Our data suggest that 510 position 154 could further regulate IFNλ4 secretion. Aside from the changes in 511 secretion we find evidence that 512 K154 when correcting for the difference in amounts of protein. This increase in 513 potency for E154 was detected in both IP protein and lysates. Moreover, we 514 observed that the difference between E and K is greater in the CM or IP fractions 515 than the cell lysate. The reason for this discrepancy could be explained by a number 516 of factors that are outside of the scope of this study. Based on our modelling of the 517
IFNλ4 structure and further mutational analysis, glutamic acid is apparently the 518 optimal residue at position 154.
519
At the biochemical level, glutamic acid has the capacity to form electrostatic 520 bonds with charged residues in the IFNλ4 protein and moreover it possesses a side 521 chain which could contribute greater flexibility for such interactions. Notably, 522
replacing glutamic acid with either aspartic acid or glutamine gave higher IFNλ4 523 activity than either non-polar or positively-charged residues. These potential E154-524 mediated interactions occur in the region of the protein devoid of cysteine-bonds 525 likely making the interaction between helix F (IFNλR1-binding) and the loop 526
connecting helices C and D (IL-10-R2-binding) particularly flexible. The putative 527 greater structural stability facilitated by E154 may inherently increase the structural 528
integrity of IFNλ4 making this variant more competent for secretion and more potent 529
in signalling through the IFNλR1-IL10R2 surface receptor complex. Increased 530 binding to IFN receptor complexes has been shown to enhance signalling by type I 531
IFNs (57,58). Further biophysical studies using highly-purified recombinant protein 532 measuring affinity and avidity of HsIFNλ4 wt and K154E for each receptor molecule 533
(as in 27,37) combined with studies on the mechanism of IFNλ4 release will help 534 address these hypotheses. 535
To conclude, our study further supports a significant and non-redundant role 536
for IFNλ4 in controlling the host response to viral infections yet one whose activity 537 has been repeatedly attenuated during human evolution, commencing with E154K, 538
with the exception of particular African hunter-gatherer groups. Taken together, this 539
provides the foundation for more detailed investigation into the mechanism of action 540
of IFNλ4 and its overall contribution to host immunity in regulating pathogen 541
infection Structural modelling 588
The homology model of the HsIFNλ4 structure used in Fig 6 and S8 Fig was  589 generated using the RaptorX online server (http://raptorx.uchicago.edu). The 590 resultant HsIFNλ4 structural model was then structurally aligned with both HsIFNλ1 591 (PDB 3OG6) (36) and HsIFNλ3 (PDB 5T5W) (37). Visualization, structural 592 alignments, and figures were generated in Pymol (The PyMOL Molecular Graphics 593
System, Version 1.8).
595
Recombinant DNA manipulation and generation of IFNλ expression plasmids 596
DNA sequences encoding the ORFs of HsIFNλ4, PtIFNλ4 and MmIFNλ4 597 (based on accession numbers above) were synthesized commercially with a 598 carboxy-terminal DYKDDDDK/FLAG tag using GeneStrings or Gene 599
Synthesis technology (GeneArt). As a positive control for functional assays, the 600 HsIFNλ3 ORF was codon optimised (human) to ensure robust expression and 601 antiviral activity, and is termed 'HsIFNλ3op'. All IFNλ4 coding region sequences were 602 retained as the original nucleotide sequence without optimisation. Synthesized DNA 603
was cloned into the pCI mammalian expression vectors (Promega) using standard 604 molecular biology techniques. At each cloning step, the complete ORF was 605 sequenced to ensure no spurious mutations had occurred during plasmid generation 606 and manipulation. Single amino acid changes were incorporated using standard site-607 directed mutagenesis protocols (QuickChange site-directed mutagenesis kit 608
[Agilent], or using overlapping oligonucleotides and Phusion PCR). 609 610
Cell lines 611 A549 (human lung adenocarcinoma), Huh7 (human hepatoma), HEK293T 612
(human embryonic kidney), U2OS (human osteosarcoma), Vero (African Green 613
Monkey kidney) and MDCK (Madin-Darby canine kidney) cells were grown in DMEM 614 growth media supplemented with 10% FBS and 1% penicillin-streptomycin. Non-615 differentiated human hepatic progenitor HepaRG cells and genome-edited 616 derivatives were cultured in William's E medium supplemented with 10% of FBS, 1% 617 penicillin-streptomycin, hydrocortisone hemisuccinate (50 µM) and human insulin (4 618 µg/mL). All cells were grown at 37°C with 5% CO 2 . Cell lines were routinely tested 619
for mycoplasma and no contamination was detected. 620 621
Plasmid transfection and production of functional IFNλ 622
Plasmid DNA generated from bacterial cultures (GeneJET plasmid midiprep 623 kit, ThermoScientific) was introduced into cells by lipid-based transfection using 624
Lipofectamine 2000 or Lipofectamine 3000 (ThermoFisher) following manufacturer's 625 instructions. To produce IFN-containing conditioned media (CM) or measure protein 626 production, HEK293T 'producer' cells were grown to near-confluency in 12 (~4 x 10 5 627 cells per well) or 6-well (~1.2 x 10 6 cells per well) plates and transfected 628 with plasmids (2 µg) in OptiMEM (1-2 ml) overnight. At approximately 16 hours (hrs) 629 post transfection (hpt), OptiMEM was removed and replaced with complete growth 630 media (1-2 ml). CM containing the extracellular IFNλs was harvested at 48 hpt and 631 stored at -20ºC before use. Although antiviral activity was observed at 16 hpt, we 632 chose 48 hpt to harvest CM to ensure robust production and secretion of each IFNλ. 633
Intracellular IFNλs also were harvested from transfected cells at 48 hpt. CM was 634 removed and replaced with fresh DMEM 10% FCS (2 ml) and then frozen at -70ºC. 635
To prepare cell lysates with IFNλ activity, plates were thawed and the cell monolayer 636 was scraped into the media and clarified by centrifugation (5 minutes [mins] x 300 g) 637 before use. CM or lysates were diluted in the respective growth medium for each cell 638 line before functional testing as described in the text. Two-fold serial dilutions of CM 639
were used in titration of anti-EMCV activity and ability to induce EGFP in an IFN-640
reporter cell line. Single CM dilutions of 1:4 (HepaRG and A549) or 1:3 (Huh7) were 641 chosen based on initial experiments for gene expression and non-EMCV antiviral 642 activity measurements to allow measurement of both high and low activity variants. 643 644 junctions mapped against the human reference transcriptome hg38 using Tophat2 689
with the default settings except library type. Transcriptome assembly was performed 690
using Cufflinks supplying annotations from the reference genome hg38 and the 691 differential gene expression was calculated using Cuffdiff. Differential gene 692 expression was considered significant when the observed fold change was ≥2.0 and 693 FDR/q-value was <0.05 between comparisons. Pathway analysis was carried out 694
using Ingenuity Pathway Analysis [IPA] (Ingenuity Systems, Redwood City, CA, 695 USA). 696 697
Western blot analysis 698
Cell growth media was removed and monolayers were rinsed once with 699 approximately 0.5 ml PBS before lysis using RIPA buffer (ThermoFisher) 700
containing protease inhibitor cocktail (1x Halt Protease inhibitor cocktail, 701
ThermoFisher, or cOmplete ™ , Mini, EDTA-free Protease Inhibitor Cocktail, Sigma 702
Aldrich) for 10 mins at 4ºC before being frozen at -20 o C overnight. Lysates were 703
collected into a 1.5 ml sample tube and clarified by centrifugation (12,000 x g for 15 704 mins). Samples (10 µl) from the soluble fraction were heated to 90ºC for 10 mins 705
with 100 mM dithiothreitol (DTT)-containing reducing lane marker at 90ºC for 10 706
mins. Samples were run on home-made 12% SDS-PAGE gels alongside molecular 707
weight markers (Pierce Lane marker, Thermofisher) before wet-transfer to 708 nitrocellulose membrane. Membranes were blocked using a solution of 50% PBS 709 and 50% FBS for 1 hr at room temperature and then incubated overnight at 4 o C with 710 primary antibodies in 50% PBS, 50% FBS and 0.1% TWEEN 711 20. Secondary antibodies were incubated in 50% PBS, 50% FBS and 0.1% TWEEN 712 20 for 1 hr at room temperature. Membranes were washed four times (5 mins each) 713
following each antibody incubation with PBS containing 0.1% TWEEN 20. After the 714 4 th wash following incubation with the secondary antibody, the membrane was 715 washed once more in PBS (5 mins) and kept in ddH 2 0 until imaging. Primary 716
antibodies to the FLAG tag (1:1000) (rabbit, lot. 064M4757V, LiCor) and α-717 tubulin (1:10000) (mouse, lot. GR252006-1, LiCor) were used along with infra-red 718 secondary antibodies (LI-COR) to anti-rabbit (donkey [1:10,000], 926-68073) and 719
anti-mouse (donkey [1:10,000], C50422-05) to allow protein visualisation. Pre-720 stained, Pageruler Plus marker was used to determine molecular weights 721 (ThermoFisher). Membranes were visualised using the LI-COR system on an 722
Odyssey CLX and the relative expression level of proteins determined using LI-COR 723 software (Image Studio). 724 725
Generation and use of IFN reporter cell lines 726
An IFN reporter HepaRG cell line was generated to measure IFN activity by 727
introducing the EGFP ORF fused to the ISG15 ORF separated by ribosome skipping 728 sites by CRISPR-Cas9 genome editing. We chose to introduce EGFP in-frame to the 729 N-terminus of the ISG15 ORF since it is a robustly-induced ISG. We also introduced 730 the blasticidin resistance gene (BSD) for selection purposes. BSD, EGFP and ISG15 731
were separated using ribosome skipping 2A sequences (P2A and T2A). Transgene 732 DNA was flanked by homology arms with reference to the predicted target site. 733
Homology donor plasmids for CRISPR-Cas9 knock-in were generated through a 734 series of overlapping PCR amplifications using Phusion DNA polymerase followed 735 by sub-cloning into pJET plasmid. Plasmids for CRISPR-Cas9 genome editing (wt 736 SpCas9) were generated using established protocols (61) in order to create plasmids 737 that would direct genome editing at the 5' terminus of the HsISG15 ORF (exon 2). 738 pSpCas9(BB)-2A-Puro (PX459) V2.0 was a gift from Feng Zhang (Addgene plasmid 739 # 62988). All sequences are available by request. HepaRG cells grown in 6 well 740 dishes were co-transfected with CRISPR-Cas9 editing plasmids targeting the 741 beginning of the ISG15 ORF in exon 2 (exon 1 contains only the ATG of the ORF), 742 and homology donor plasmids described above (1 µg each) using Lipofectamine 743 2000 and the protocol described above. Transfected cells were selected using 744 puromycin (Life Technologies) (1 µg/ml) and blastocidin (Invivogen) (10 µg/ml) until 745 non-transfected cells were no longer viable. Selected cells were cloned by single cell 746 dilution, expanded and tested for EGFP induction following IFN stimulation. 747
Positioning of the introduced transgene was assessed by PCR amplification on 748 isolated genomic DNA from individual clones (data not shown). Primers were 749 designed to include one primer internal to the transgene and another external to the 750 transgene and found in the target loci (sequences available on request). For use as 751
an effective IFN reporter cell line, cells had to demonstrate robust induction of EGFP 752 expression following stimulation with IFN and evidence of specific introduction of the 753
transgene. This study uses clone 'G8' of HepaRG.EGFP-BSD-ISG15 cells. We have 754 not tested whether there is a single transgene integration site or multiple ones nor 755
confirmed that the EGFP produced following stimulation by IFNs results from the 756 expression of the specifically-introduced transgene rather than off-target integration, 757
which is theoretically possible. We do not predict this would affect the cells' ability to 758
act as a reporter cell line. For use in IFN reporter assays, stimulated cells (in 96 well 759
plates stimulated for 24 hrs; ~5 x 10 4 cells per well) were washed, trypsinised and 760 fixed in formalin (1% in PBS) at room temperature for 10 mins in the dark before 761 being transferred to a round-bottomed plate and stored at 4 o C in the dark until 762 measurement of EGFP fluorescence. Non-stimulated cells were used as negative 763
controls and the change in % EGFP-positive cells was assessed by flow cytometry 764 using a Guava easyCyte HT (Merck Millipore). For fluorescence microscopy, EGFP 765 induction was measured by indirect immunofluorescence of stimulated cells that 766
were fixed and permeabilised on coverslips prior to antibody binding. An EGFP 767 primary antibody (1:1000, rabbit ab290 Abcam) was used followed by a fluorescent 768 anti-secondary antibody (1:500, Goat anti Rabbit Alexa-Fluor, Thermo Fisher, 769 568nm). Samples were counter-stained using DAPI and visualised with a confocal 770 laser-scanning microscope (Zeiss LSM 710) under identical conditions. 771 772
Production of virus stocks for antiviral assays 773 Antiviral activity of IFNλs was determined using encephalomyocarditis virus 774 (EMCV), influenza A virus (IAV; A/WSN/1933(H1N1)), Zika virus (ZIKV; Brazilian 775 strain PE243)(62) and HCV (HCVcc chimeric clone Jc1) (63). EMCV was grown on 776 Vero cells followed by titration on U2OS cells by plaque assay. IAV stocks were 777 generated on MDCK cells and titrated by plaque assay on MDCK cells with protease 778
(TPCK-treated trypsin, Sigma Aldrich). ZIKV was titrated on Vero cells by plaque 779 assay. For all plaque assays, cells were grown in 12 or 6-well plates to ~90% 780 confluency before inoculation with serial 10-fold dilutions of virus stocks in serum-781 free Optimem. Inoculum remained on the cells for 2 hrs before removal and the 782 monolayers were rinsed with PBS (1x) and semi-solid Avicell overlay (Sigma Aldrich) 783
was added. For EMCV and IAV, 1.2% Avicell was used, diluted in 1x DMEM 10% 784 FCS, 1% penicillin-streptomycin. For IAV titration, TPCK-treated trypsin was added 785
(1 µg/ml). For ZIKV plaque assay, 2x MEM was used instead of 1x DMEM. HCVcc 786 Jc1 was generated as described previously by electroporation of in vitro transcribed 787 viral RNA into Huh7 cells and harvested at 72 hrs post electroporation. After filtration 788 of the supernatant, HCVcc Jc1 stocks were titrated by TCID 50 on Huh7 cells and 789 stored at 4 o C before use. HCVcc Jc1 TCID 50 assays were performed using anti-790
NS5A antibody (64). Infected cells at 72 hrs post infection were fixed 791
and permeabilised with ice-cold methanol. Cells were rinsed in PBS, blocked with 792 3% FCS in PBS at room temperature and incubated overnight with mouse 793 monoclonal anti-NS5A antibody (9E10) at 4 o C. After removal of the antisera, cells 794
were rinsed 3 times with PBS containing 0.1% TWEEN 20, and then incubated in the 795 dark at room temperature for 1 hr with secondary antibody [Alexa-fluor 488nm anti-796 mouse (donkey)]. Cells were finally washed with PBS containing 0.1% TWEEN 20 797
and NS5A-expressing cells were visualized with a fluorescent microscope. 798 799
Antiviral assays 800
Cells stimulated with IFNλs were infected with viruses at the following 801 multiplicities of infection (MOI): EMCV (MOI = 0.3; added directly to the media); IAV 802
(MOI = 0.01); ZIKV (MOI = 0.01); HCVcc (MOI = 0.05). For IAV, ZIKV and HCVcc, 803
the inoculum was incubated with cells for at 2 (IAV/ZIKV) or 3 hrs (HCVcc) in 0.5-1.0 804 ml serum-free Opti-MEM/DMEM at 37 o C before removal. Cells were rinsed with PBS 805
and then incubated with fresh growth media for the allotted time (24 hrs for EMCV, 806
48 hrs for IAV and 72 hrs for ZIKV and HCVcc). At the times stated for individual 807 experiments, infected-cell supernatants were harvested and infectivity was titrated by 808 plaque assay. IAV, ZIKV and HCVcc antiviral assays were all carried out in 12 well 809
plates except for measurement of HCVcc infectivity by indirect immunofluorescence, 810 which was measured in a 96 well plate. In the case of EMCV, a cytopathic effect 811 (CPE) protection assay was employed to assess infectivity (26). Here, HepaRG cells 812
were plated in a 96-well plates (~5 x 10 4 cells per well) and, when confluent, were 813 incubated with two-fold serial dilutions of CM or lysate for 24 hrs before the addition 814 of EMCV. At 24 hrs post infection with EMCV, media was removed, cell monolayers 815
were rinsed in PBS and stained using crystal violet (1% in 20% ethanol in H 2 0) for 10 816 mins. Crystal violet stain was then removed and stained plates were washed in 817
water. The dilution of ~50% inhibition of EMCV-induced CPE was marked visually 818 and the difference determined relative to wt HsIFNλ4. 819
Luciferase-expressing MLV pseudoparticles containing the E1 and E2 820 glycoproteins from JFH1 HCV strain were generated as described (65) dataset included individuals with IL28B rs12979860 genotypes T/T, C/T and C/C but 858 no association between IL28B genotype and gene expression was noted (31). Gene 859 names and fold-changes were manually converted to a single format (fold change 860 rather than log2 fold change for example) to allow comparative analysis. Human 861 biopsies were taken between two and five months after presumed infection following 862 known needle-stick exposure, and serial chimpanzee biopsies were taken at different 863 time points from between one week and one year after HCV infection. For 864 comparative purposes, differentially-expressed genes in chimpanzees were included 865 if they were detected during a time period overlapping with the human data. We 866 identified a 'core' set of chimpanzee differentially-expressed genes (independently 867 characterized in at least two studies) and compared them to the single human 868 transcriptome study data at equivalent time points (between 8 and 20 weeks post-869 infection). This approach generated a set of core chimpanzee genes (genes found 870 differentially-expressed in at least 2 studies, >2 fold change compared to controls 871 and during the time frame compared to humans) for comparison with the human 872
data. This is reflected in the ten-fold higher numbers of differentially-regulated genes 873
found in the one human study compared to the 'core' (reduced) set assembled from 874
four chimpanzee studies. To validate these findings, we used three studies of 875 chronic infection for which data were available (53,67,68), two from humans 876 employing RNA-Seq and one from chimpanzees using microarray measurement. 877
Gene lists were extracted and a core human list was produced and compared to that 878 from chimpanzees. For shared genes, the fold change values were compared for 879
humans and chimpanzees. The ratio of chimpanzee induction to human induction 880 was calculated. 881
These gene sets were compared to determine their degree of species 
